Business Standard MUMBAI | MONDAY, 20 MAY 2019

PASPIRA"

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

CIN: - L85100MH1973PLC289209

Reg. Office: Flat No.2, R.D.Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W.), Mumbai -400086

Corporate office: Plot no.6, RPT House, Sector 24, Turbhe, Navi Mumbai - 400705
Tel No.: 71975656; email ID: info@aspiradiagnostics.com; website: www.aspiradiagnostics.com
Extracts of Audited Financial Results for the Quarter & Year Ended March 31, 2019

(Rupees in Lakhs)

Sr. No	Particulars	Quarter Ended 31/03/2019 (Audited)	Year ended 31/03/2019 (Audited)	Quarter ended 31/03/2018 (Audited)
1.	Total income from operations	215.23	789.03	457.83
2.	Net Profit / (Loss) for the period (before Tax,		Selection of	ment of
T.	Exceptional and /or Extraordinary items#)	(124.40)	(518.29)	(558.23)
3.	Net Profit / (Loss) for the period before tax			
	(after Exceptional and/or Extraordinary items#)	(124.40)	(518.29)	(558.23)
4.	Net Profit / (Loss) for the period after tax		No. of London	
	(after Exceptional and/or Extraordinary items#)	(124.40)	(518.29)	(558.23)
5.	Total Comprehensive Income for the period			
	(Comprising profit/(loss) for the period(after tax)	lo de la la		
Pa	and other Comprehensive Income(after tax)	(124.40)	(517.32)	(558.13)
6.	Equity Share Capital	819.30	819.30	519.30
7.	Reserves (excluding Revaluation Reserve) as shown			
	in the Audited Balance Sheet of previous year)			
8.	Earnings Per Share (of ? 10/- each)	al some		
	(for continuing and discontinued operations)-	Company In such		
	Basic:	(1.52)	(6.31)	(10.75)
	Diluted:	(1.78)	(7.40)	(10.75)

Note

a. The above is an extract of the detailed format of Audited Financial Results for the Quarter & Year ended March 31, 2019, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Year ended 31st March 2019 is available on the websites of the Stock Exchange(s) and the company's website: - www.aspiradiagnostics.com.

b. 'The above result has been reviewed by the Audit Committee and approved by Board of Directors at their meeting held on May 18, 2019

For and on behalf of the Board For Aspira Pathlab & Diagnostics Limited Pankaj Shah

(Managing Director) DIN: - 02836324

(mail

Place: - Mumbai Date: - May 18, 2019



ASPIRA PATHLAB & DIAGNOSTICS LIMITED SASPIRA"

CIN: - L85100MH1973PLC289209 Reg. Office: Flat No.2, R.D.Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W.), Mumbai -400086

Corporate office : Plot no.6, RPT House, Sector 24, Turbhe, Navi Mumbai - 400705 Tel No.: 71975656 ; email ID: info@aspiradiagnostics.com ; website: www.aspiradiagnostics.com Extracts of Audited Financial Results for the Quarter & Year Ended March 31, 2019

		(Rupees in Lakhs)		
Sr	Particulars	Quarter Ended 31/03/2019 (Audited)	Year ended 31/03/2019 (Audited)	Quarter ended 31/03/2018 (Audited)
1.	Total income from operations Net Profit / (Loss) for the period (before Tax,	215.23	789.03	457.83
3.	Exceptional and /or Extraordinary items#) Net Profit / (Loss) for the period before tax	(124.40)	(518.29)	(558.23)
4.	(after Exceptional and/or Extraordinary items#) Net Profit / (Loss) for the period after tax	(124.40)	(518.29)	(558.23)
5.	(after Exceptional and/or Extraordinary items#) Total Comprehensive Income for the period	(124.40)	(518.29)	(558.23)
	(Comprising profit/(loss) for the period(after tax) and other Comprehensive Income(after tax)	(124.40)	(517.00)	1000
5.	Equity Share Capital Reserves (excluding Revaluation Reserve) as shown	819.30	(517.32) 819.30	(558.13) 519.30
	in the Audited Balance Sheet of previous year) Earnings Per Share (of ? 10/- each)			
1	(for continuing and discontinued operations)- Basic:	loss no s		
	Diluted:	(1.52)	(6.31)	(10.75)
ote:		(1.78)	(7.40)	(10.75)

The above is an extract of the detailed format of Audited Financial Results for the Quarter & Year ended March 31, 2019, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Year ended 31st March 2019 is available on the websites of the Stock Exchange(s) and the company's website: - www.aspiradiagnostics.com.

The above result has been reviewed by the Audit Committee and approved by Board of Directors at their meeting held on May 18, 2019

For and on behalf of the Board For Aspira Pathlab & Diagnostics Limited

Place: - Mumbal Date: - May 18, 2019

Pankaj Shah (Managing Director) DIN: - 02836324